IFM Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
855 Boylston St Fl 11, Boston, Massachus...Phone Number
(857) 304-0583Website
www.ifmthera.comRevenue
$23 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IFM Therapeutics
IFM Therapeutics is dedicated to enhancing the lives of patients suffering from inflammation-driven diseases and cancer by developing innovative medicines that target the innate immune system. The company focuses on creating first-in-class small molecules that regulate immune responses across various disease indications. With a strong track record of advancing novel programs from discovery to clinical studies, IFM Therapeutics aims to address the urgent needs of patients. Their portfolio includes several promising drug candidates currently in various stages of development.Explore more
IFM Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IFM Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if IFM Therapeutics had a recent Job posting/layoffs
IFM Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if IFM Therapeutics is spiking on competitors!
Product Launch: Get notified when IFM Therapeutics launches new products
Check if IFM Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on IFM Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at IFM Therapeutics
Funding: Get notified immidiatlly once IFM Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to IFM Therapeutics
Compare insights from companies similar to IFM Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IFM Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IFM Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IFM Therapeutics.
IFM Therapeutics financials insights
Gather financial insights about IFM Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$27M
2019
Unspecified
$55.5M
IFM Therapeutics Tech Stack
A closer look at the technologies used by IFM Therapeutics
Most Recent Scoops
Left Company
Executive Move
New Hire
Executive Move
Stephanos Ioannidis has been named Executive Vice President, Head of Discovery. Previously, Ioannidis served as Vice President, Head of Chemistry at H3 Biomedicine.
New Hire
Executive Move
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
IFM Therapeutics News & Media
IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due
BOSTON, Dec. 1, 2021 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced that IFM Due, an IFM subsidiary company, has extended its collaboration and...IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
BOSTON, Jan. 7, 2020 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the appointment of Michael Cooke, Ph.D., as Chief Scientific Officer. In his...IFM Therapeutics Raises $55.5M in Financing
IFM Therapeutics (IFM), a Boston, MA-based biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, closed a $55.5m financing. The round was led by new investor Omega Funds, with participation from existing investors Atlas Venture and Abingworth. In conjunction with the financing, Paulina Hill of Omega Funds will join […] The post IFM Therapeutics Raises $55.5M in Financing appeared first on FinSMEs.IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator
IFM Therapeutics has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers. Those endeavors will be led by a familiar face. Boston-based IFM has promoted its vice president of research and development, Martin Seidel, to become […]
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding IFM Therapeutics
Sign Up For FreeTo access detailed company insights
IFM Therapeutics is dedicated to enhancing the lives of patients suffering from inflammation-driven diseases and cancer by developing innovative medicines that target the innate immune system. The company focuses on creating first-in-class small molecules that regulate immune responses across various disease indications. With a strong track record... Read More
